rethinkPeptides Search
Menu
Study breakdown

Endogenous Opioid Pain Control at the Site of Injury: Clinical Applications for Peripheral Analgesia

ReviewModerate evidence
The takeaway

Immune cells at injury sites release opioid peptides that control pain locally through peripheral opioid receptors — a clinically exploitable mechanism for pain relief without central side effects like addiction and sedation.

Key finding

Peripheral endogenous opioid analgesia from immune cell-released peptides at inflammation sites provides clinically significant pain control through p

What the researchers found

Peripheral endogenous opioid analgesia from immune cell-released peptides at inflammation sites provides clinically significant pain control through peripheral opioid receptors, exploitable with intra-articular, topical, and peripherally-restricted opioid drugs without CNS side effects.

Why it matters

Relevant for opioid-peptides, pain, inflammation, immune-function.

How the study worked

review study on opioid-peptides, pain.

What this study cannot tell us

See abstract.

How to read the evidence

moderate evidence.

When this study was published

Published in 2005.

The bigger picture

Advances peptide research with clinical implications.

Questions still open

  • Further research needed.
  • Clinical translation to evaluate.

Common questions

What was studied?
Endogenous Opioid Pain Control at the Site of Injury: Clinical Applications for Peripheral Analgesia
What was found?
Immune cells at injury sites release opioid peptides that control pain locally through peripheral opioid receptors — a clinically exploitable mechanism for pain relief without central side effects like addiction and sedation.

Read the original research

Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control.

Therapeutics and clinical risk management, 1(4), 279-97

Citation

Kapitzke, Daniel; Vetter, Irina; Cabot, Peter J. (2005). Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control.. Therapeutics and clinical risk management, 1(4), 279-97.